The Longfellow Letter

In late 2025, data is easy to get. Insight is rare. Biotech winners use AI to turn data into real drug decisions, not just bigger datasets.

The theme for November is The Great Rationalization. After a protracted downturn, the market is forcing a painful but necessary reckoning.

Biotech insights and innovation: Pasteur’s perseverance, Biogen’s shifts, Fractyl’s breakthrough, and the evolution of monoclonal antibodies.

In biotech, the era of raising on promises is on pause. We analyze recent deals & what VCs are funding now: clinically de-risked assets.